Healthcare
Markets Split as Pfizer Slumps, Circle Soars on Visa Partnership
Earnings guidance, analyst calls, and commodity moves drive sharp stock reactions U.S. stocks delivered a mixed performance Tuesday as investors...
Pfizer Flags Softer 2026 Outlook as COVID-19 Sales Continue to Fade
Lower demand for pandemic-era products weighs on earnings and revenue forecasts Pfizer (PFE) shares edged lower in premarket trading on...
Structure Therapeutics Reports Breakthrough Weight-Loss Results for Oral GLP-1 Candidate Aleniglipron
Phase 2b and ACCESS II studies show up to 15.3% weight reduction with promising tolerability, positioning aleniglipron as a potential...
Polyrizon Achieves Key Manufacturing Milestone for Its Intranasal Allergy Protection Platform
Successful scale-up of PL-14 production paves the way for 2026 clinical trials and future commercial readiness. Polyrizon (PLRZ), a biotechnology...
A Breakthrough in Knee Osteoarthritis: Enlivex Reports Promising Six-Month Results for Allocetra
Sustained pain reduction, improved mobility, and strong safety profile position Allocetra™ as a potential game-changer for aging patients Enlivex Therapeutics...
Eli Lilly and Novo Nordisk Strike Weight-Loss Drug Deal with Trump Administration
Landmark agreement cuts drug prices, expands Medicare access, and grants tariff relief to leading obesity drugmakers Eli Lilly & Co....
Pfizer, Novo Nordisk Eye Metsera; Sarepta Sinks, Hertz Surges
Tuesday’s trading session saw major pharmaceutical deals, biotech setbacks, and a surprise comeback in the car rental sector. On Tuesday’s...
Kimberly-Clark and Kenvue Unite to Form Consumer Health Giant
Kimberly-Clark, the maker of household staples like Kleenex and Huggies, has announced plans to acquire Tylenol producer Kenvue in a...
Intensity Therapeutics Publishes Promising Phase 1/2 Results for Novel Cancer Drug INT230-6
Study in eBioMedicine shows strong disease control and survival benefits across multiple tumor types with minimal toxicity Intensity Therapeutics (INTS),...
Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240
Achievement validates CAPTN-3 platform scalability and advances IM1240 toward first-in-human clinical trials in 2026 Purple Biotech (PPBT), a clinical-stage biotechnology...
